ElevenLabs could start preparing for an IPO in 2028, its CEO says

ElevenLabs CEO Mati Staniszewski said the company could start preparing for an IPO in 2028, and expressed a desire to build a public company. The remarks were made at Bloomberg Tech in London; no valuation, offering size, or firm IPO timetable was provided.

Analysis

The IPO reference is a long-dated strategic signal, not a near-term earnings catalyst: there is no stated timetable, filing, or quantified operating milestone. Treat it as an aspiration until supported by financing, governance, and disclosure steps. In the next few months, the more useful signal is whether ElevenLabs demonstrates durable paid demand and can defend pricing as generative-audio tools become easier to replicate. A credible path to public-market readiness could help with employee retention and fundraising, but also raises expectations around usage economics, rights management, and controls against voice misuse.

The contrarian read is that public-market ambition may be less a valuation signal than an effort to preserve strategic optionality in a competitive market. A 2028 horizon leaves ample room for conditions to change; IPO plans can be delayed or abandoned, and any eventual listing could face a weaker window. Over 6–18 months, watch for evidence that differentiation translates into repeat enterprise revenue rather than trial-driven usage, alongside regulatory or litigation developments affecting voice cloning. No listed-company proxy offers clean exposure to this company-specific outcome, so a thematic trade would likely dilute the thesis.

Key Decisions for Investors

• No immediate trade: do not treat the comment as a listed-equity catalyst or infer an IPO valuation from it.
• Set a watchlist trigger for verifiable IPO-readiness steps—such as a disclosed financing, formal governance changes, or sustained financial reporting—rather than relying on further aspirational statements.
• Track paid-customer retention, enterprise adoption, and pricing relative to competing voice-generation tools; deterioration in these measures would weaken the IPO-readiness thesis.
• Monitor regulation and litigation involving synthetic voice and consent. A material restriction or adverse ruling could impair the addressable market; clearer rules that support licensed use could reduce that risk.